A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)

PHASE3UnknownINTERVENTIONAL
Enrollment

28,000

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 Vaccine (Vero Cells), Inactivated

2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.

BIOLOGICAL

Placebo

2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.

Sponsors
All Listed Sponsors
collaborator

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY

lead

Shenzhen Kangtai Biological Products Co., LTD

INDUSTRY